- info@saudicanadianbiotech.com
led by passionate experts
The Canada–Saudi Biotech Corridor Where Innovation Meets Scale. Where Science Meets Vision.
A bilateral innovation platform uniting Canada’s world-class biotech ecosystem with Saudi Arabia’s capital, ambition, and localization power — building the future of biotechnology together.
Why This Corridor Exists
Not a partnership. Not an event. A new global biotech bridge.
This corridor is about ecosystem creation.
It connects innovation with scale, science with capital, and ideas with execution.
Canada brings validated technologies.
Saudi Arabia brings acceleration, localization, and market power.
- Innovation
- Capital
- Scale
- Translation
- Impact
OUR SPECIALTIES
What Makes It Different
Standing Guard
Corridor Pillars
Building Human Capital and Translating Science into Impact
This pillar focuses on connecting leading academic institutions, research centers, and innovation hubs in Saudi Arabia and Canada to accelerate scientific discovery and turn research into real-world applications. It creates a dynamic pathway where ideas, people, and technologies move efficiently from universities and laboratories into industry and healthcare.
Key objectives include:
- Enabling joint research programs in genomics, biotechnology, AI in healthcare, and advanced therapeutics
- Supporting technology transfer and commercialization of academic innovations
- Establishing structured exchange programs for students, post-doctoral fellows, clinicians, and scientists
- Promoting co-supervised PhD and fellowship programs between Saudi and Canadian institutions
- Facilitating short-term sabbaticals and visiting professorships
This pillar ensures the Corridor becomes a living ecosystem where talent circulates, innovation is translated, and future biotech leaders are continuously developed.
Transforming Innovation into Scalable Biotech Ventures
This pillar serves as the financial and entrepreneurial engine of the Corridor. It connects Saudi capital with Canada’s biotech innovation pipeline to create investable, scalable, and globally competitive biotechnology companies.
Key objectives include:
- Establishing a joint Saudi–Canadian biotech accelerator and incubation platform
- Supporting early-stage startups through mentorship, funding access, and regulatory guidance
- Structuring co-investment vehicles and venture partnerships
- Enabling soft-landing programs for Canadian startups entering the Saudi market and vice versa
- Supporting spin-offs from universities and research centers into commercial ventures
This pillar ensures that scientific breakthroughs do not remain in laboratories but become sustainable companies, new industries, and long-term economic value aligned with Vision 2030.
Advancing Personalized Healthcare Through Data and Science
This pillar focuses on building a world-class ecosystem for genomics, multi-omics, and precision medicine. It enables collaboration in population genomics, AI-driven risk prediction, diagnostics, and personalized therapeutics tailored to regional populations.
Key objectives include:
- Developing joint genomics and precision medicine programs
- Supporting population-scale genomic studies and biobanking
- Advancing Polygenic Risk Scores (PRS), pharmacogenomics, and multi-omics platforms
- Promoting clinical integration of genomics into routine healthcare
- Building secure, ethical, and compliant genomic data infrastructure
This pillar positions the Corridor as a leader in translating genomic science into improved patient outcomes, preventive healthcare, and national health intelligence.
From Discovery to Global-Scale Delivery
This pillar bridges research, clinical validation, and industrial production. It enables Saudi Arabia and Canada to collaborate across the full lifecycle of biotechnology development, from clinical trials to manufacturing and global deployment.
Key objectives include:
- Establishing joint clinical trial networks and regulatory alignment
- Attracting global biotech companies to conduct trials in the Corridor ecosystem
- Developing regional biomanufacturing capabilities for diagnostics, biologics, and advanced therapies
- Supporting technology transfer in GMP manufacturing
- Strengthening supply chain resilience and localization strategies
This pillar transforms the Corridor into a complete biotech value chain platform, capable of discovering, validating, producing, and exporting advanced healthcare solutions.
The Way Forward
The Roadmap
February 2026 – Riyadh
Corridor foundation & quick wins identified
July 2026 – Toronto
Working summit. Deals shaped. MOUs signed. Projects launched
October 2026 – GHE Riyadh
Global showcase of real outcomes
“This corridor operationalizes vision into reality. It transforms ambition into execution.”
Guided by leadership. Driven by community.
Leadership
Dr. Abdulelah Alhawsawi
🇸🇦 Saudi Lead
Co-Founder & CEO, Novo Genomics
Jeff Graham
🇨🇦 Canadian Lead
President, Canadian BioPartners International
our inititive
Be Part of the Founding Generation of a Global Biotech Corridor
